Table 2

Clinical characteristics of study participants

CAVSCADP value
Number of patients476414
Men271 (57)235 (57)0.93
Age, years72.0 (8.7)71.1 (8.7)0.10
Body mass index, kg/m2 28.1 (5.2)27.5 (4.3)0.03
Active smokers48 (10)48 (12)0.43
Coronary artery disease244 (51)414 (100)<0.0001
Diabetes140 (29)126 (30)0.75
Hypertension339 (71)291 (70)0.54
Lipid-lowering therapy306 (64)341 (82)<0.0001
Total cholesterol, mmol/L4.35 (1.07)4.06 (0.99)<0.0001
LDL cholesterol, mmol/L2.41 (0.91)2.21 (0.80)0.0004
HDL cholesterol, mmol/L1.26 (0.36)1.15 (0.34)<0.0001
Apolipoprotein B, g/L0.71 (0.21)0.66 (0.20)<0.0001
Triglycerides, mmol/L1.51 (0.81)1.56 (0.77)0.30
Creatinine, μmol/L96.6 (40.2)91.9 (20.1)0.02
Lp-PLA2, μmol/min/mL0.017 (0.005)0.016 (0.005)<0.0001
  • Data are presented as mean (SD) or n (%).

  • CAD, coronary artery disease; CAVS, calcific aortic valve stenosis; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2.